| (Values in U.S. Thousands) | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -24,790 | -17,680 | -11,250 | -15,660 | -7,160 |
| Net Income Growth | -40.21% | -57.16% | +28.16% | -118.72% | +14.66% |
Forte Biosciences Inc (FBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Forte Biosciences Inc. is a clinical stage, dermatology company. It engages in developing biotherapeutic, FB-401, for the treatment of inflammatory skin diseases which is in clinical stage. Forte Biosciences Inc., formerly known as Tocagen Inc., is based in Sherman Oaks, California.
Fiscal Year End Date: 12/31